Royalty Pharma plc [NASDAQ: RPRX] surged by $0.36 during the normal trading session on Friday and reaching a high of $36.765 during the day while it closed the day at $36.70. The company report on October 21, 2020 that Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders.
Royalty Pharma plc (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per share. The Company did not receive any of the proceeds from the sale of its Class A ordinary shares by the selling shareholders.
J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC and Citigroup acted as joint lead book-running managers and as representatives of the underwriters for the offering. Cowen, Evercore ISI, Truist Securities and UBS Investment Bank also acted as joint book-running managers for the offering. BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners acted as co-managers for the offering.
The market cap for RPRX stock reached $22.06 billion, with 353.98 million shares outstanding and 56.78 million shares in the current float. Compared to the average trading volume of 1.26M shares, RPRX reached a trading volume of 1157408 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Royalty Pharma plc [RPRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RPRX shares is $52.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RPRX stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Royalty Pharma plc shares, keeping their opinion on the stock as In-line, with their previous recommendation back on July 14, 2020. While these analysts kept the previous recommendation, UBS raised their target price to Neutral. The new note on the price target was released on July 13, 2020, representing the official price target for Royalty Pharma plc stock. Previously, the target price had yet another raise to $56, while SunTrust analysts kept a Buy rating on RPRX stock.
The Average True Range (ATR) for Royalty Pharma plc is set at 1.62, with the Price to Sales ratio for RPRX stock in the period of the last 12 months amounting to 11.41. The Price to Book ratio for the last quarter was 3.13, with the Price to Cash per share for the same quarter was set at 5.56.
RPRX stock trade performance evaluation
Royalty Pharma plc [RPRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.92.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RPRX stock in for the last two-week period is set at 29.30, with the RSI for the last a single of trading hit 23.81, and the three-weeks RSI is set at 34.48 for Royalty Pharma plc [RPRX]. The present Moving Average for the last 50 days of trading for this stock 41.03, while it was recorded at 37.16 for the last single week of trading.
Royalty Pharma plc [RPRX]: An insightful look at the core fundamentals
Royalty Pharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.50.
Earnings per share (EPS) analysis for Royalty Pharma plc [RPRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RPRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Royalty Pharma plc go to 6.80%.
Royalty Pharma plc [RPRX]: Insider Ownership positions
There are presently around $5,423 million, or 43.60% of RPRX stock, in the hands of institutional investors. The top three institutional holders of RPRX stocks are: ADAGE CAPITAL PARTNERS GP, L.L.C. with ownership of 46,015,330, which is approximately New of the company’s market cap and around 0.10% of the total institutional ownership; FMR LLC, holding 16,356,491 shares of the stock with an approximate value of $600.28 million in RPRX stocks shares; and HARVARD MANAGEMENT CO INC, currently with $539.15 million in RPRX stock with ownership of nearly New of the company’s market capitalization.
122 institutional holders increased their position in Royalty Pharma plc [NASDAQ:RPRX] by around 147,731,384 shares. Additionally, 5 investors decreased positions by around 21,552 shares, while 0 investors held positions by with 105 shares. The mentioned changes placed institutional holdings at 147,753,041 shares, according to the latest SEC report filing. RPRX stock had 119 new institutional investments in for a total of 147,723,006 shares, while 4 institutional investors sold positions of 21,477 shares during the same period.